TruScreen Awarded Zimbabwe Tender

NZX/ASX Announcement 6 November 2023 TruScreen Awarded Zimbabwe Tender Truscreen Group Limited (NZX/ASX:TRU) is pleased to confirm the receipt of a further purchase order from Zimbabwe for SUS (single use sensor) with a gross sales value of approximately NZ$300,000. The SUS is the disposal consumable item used in each TruScreen cervical cancer screening test. Zimbabwe, under the auspices of the National Aids Council (NAC) program have already screened a total of 14,000 women in Masvingo province. It is expected that this initial program will be extended to a national roll out. Cervical cancer is the most prevalent and deadly cancer for women in Zimbabwe . Women living with HIV have a six-fold increased risk of cervical cancer, when compared to women without HIV . As part of the national screening project, and the ongoing partnership with NAC, TruScreen cervical cancer screening forms part of routine screening for the general population, and for women living with HIV. The CEO, Dr Beata Edling commented: "This new purchase order from Zimbabwe is confirmation that TruScreen is making a difference in ensuring that early treatment for cervical cancer significantly reduces the potential downstream health and human costs. We commend our distributor Southern Skies Medical Pvt Ltd and NAC for their ongoing support in this program". This announcement has been approved by the Board. Ends For more information, visit www.truscreen.com or contact: Dr Beata Edling Chief Executive Officer beataedling@truscreen.com Guy Robertson Chief Financial Officer guyrobertson@truscreen.com End CA:00421063 For:TRU Type:GENERAL Time:2023-11-06 08:30:15